- Home
- BNGO vs INKT Comparison
BNGO vs INKT Comparison
Compare BNGO & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNGO
- INKT
- Stock Information
- Founded
- BNGO 2003
- INKT 2017
- Country
- BNGO United States
- INKT United States
- Employees
- BNGO N/A
- INKT N/A
- Industry
- BNGO Biotechnology: Laboratory Analytical Instruments
- INKT Medicinal Chemicals and Botanical Products
- Sector
- BNGO Industrials
- INKT Health Care
- Exchange
- BNGO Nasdaq
- INKT Nasdaq
- Market Cap
- BNGO 24.3M
- INKT 28.8M
- IPO Year
- BNGO 2018
- INKT 2021
- Fundamental
- Price
- BNGO $3.40
- INKT $62.86
- Analyst Decision
- BNGO Buy
- INKT Strong Buy
- Analyst Count
- BNGO 5
- INKT 2
- Target Price
- BNGO $7.33
- INKT $37.50
- AVG Volume (30 Days)
- BNGO 84.1K
- INKT 2.4M
- Earning Date
- BNGO 08-06-2025
- INKT 08-12-2025
- Dividend Yield
- BNGO N/A
- INKT N/A
- EPS Growth
- BNGO N/A
- INKT N/A
- EPS
- BNGO N/A
- INKT N/A
- Revenue
- BNGO $28,464,000.00
- INKT N/A
- Revenue This Year
- BNGO N/A
- INKT N/A
- Revenue Next Year
- BNGO $15.54
- INKT N/A
- P/E Ratio
- BNGO N/A
- INKT N/A
- Revenue Growth
- BNGO N/A
- INKT N/A
- 52 Week Low
- BNGO $2.68
- INKT $4.56
- 52 Week High
- BNGO $41.33
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- BNGO 47.05
- INKT 57.39
- Support Level
- BNGO $3.22
- INKT $6.80
- Resistance Level
- BNGO $3.46
- INKT $7.88
- Average True Range (ATR)
- BNGO 0.15
- INKT 0.40
- MACD
- BNGO 0.02
- INKT 0.02
- Stochastic Oscillator
- BNGO 75.86
- INKT 58.86
About BNGO Bionano Genomics Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.